Matinas BioPharma (NYSEAMERICAN:MTNB – Get Free Report)‘s stock had its “hold” rating reiterated by investment analysts at Maxim Group in a research report issued on Thursday, Benzinga reports.
Matinas BioPharma Stock Down 68.1 %
MTNB traded down $1.32 during trading on Thursday, hitting $0.62. 2,865,360 shares of the stock were exchanged, compared to its average volume of 44,149. The company has a market capitalization of $3.09 million, a P/E ratio of -0.11 and a beta of 1.64. Matinas BioPharma has a 1 year low of $0.54 and a 1 year high of $21.50.
Matinas BioPharma (NYSEAMERICAN:MTNB – Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.02) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.02).
Institutional Investors Weigh In On Matinas BioPharma
About Matinas BioPharma
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Recommended Stories
- Five stocks we like better than Matinas BioPharma
- Comparing and Trading High PE Ratio Stocks
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- ESG Stocks, What Investors Should Know
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- How to Invest in Insurance Companies: A Guide
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.